Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Fc Fusion on Folding and Immunogenicity of Middle East Respiratory Syndrome Coronavirus Spike Protein

  • Chun, Jungmin (Department of Bio-industrial Technologies, Konkuk University) ;
  • Cho, Yeondong (Department of Bio-industrial Technologies, Konkuk University) ;
  • Park, Ki Hoon (Department of Bio-industrial Technologies, Konkuk University) ;
  • Choi, Hanul (Department of Bio-industrial Technologies, Konkuk University) ;
  • Cho, Hansam (Department of Biomedical Science and Engineering, Konkuk University) ;
  • Lee, Hee-Jung (Department of Biomedical Science and Engineering, Konkuk University) ;
  • Jang, Hyun (WooGene B&G) ;
  • Kim, Kyung Hyun (Department of Biotechnology and Bioinformatics, Korea University) ;
  • Oh, Yu-Kyoung (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Kim, Young Bong (Department of Bio-industrial Technologies, Konkuk University)
  • Received : 2019.03.20
  • Accepted : 2019.04.02
  • Published : 2019.05.28
Download PDF
⟨ Previous Next ⟩

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) induces severe respiratory impairment with a reported mortality rate of ~36% in humans. The absence of clinically available MERS-CoV vaccines and treatments to date has resulted in uncontrolled incidence and propagation of the virus. In vaccine design, fusion with the IgG Fc domain is reported to increase the immunogenicity of various vaccine antigens. However, limited reports have documented the potential negative effects of Fc fusion on vaccine antigens. To determine whether Fc fusion affects the immunogenicity of MERS-CoV antigen, we constructed a Fcassociated MERS-CoV spike protein (eS770-Fc, 110 kDa), whereby human IgG4 Fc domain was fused to MERS-CoV spike protein (eS770) via a Gly/Pro linker using baculovirus as the expression system. For comparative analyses, two eS770 proteins lacking the IgG4 Fc domain were generated using the IdeS protease ($eS770-{\Delta}Fc$) or His tag attachment (eS770-His) and the immunogenicity of the above constructs were examined following intramuscular immunization in mice. Contrary to expectations, non-Fc spike proteins ($eS770-{\Delta}Fc$, eS770-His; 90 kDa) showed higher immunogenicity than the Fc fusion protein (eS770-Fc). Moreover, unlike non-Fc spike proteins, eS770-Fc immunization did not elicit neutralizing antibodies against MERS-CoV. The lower immunogenicity of Fc-fused eS770 was related to alterations in the structural conformation of the spike protein. Taken together, our results indicate that IgG Fc fusion reduces the immunogenicity of eS770 by interfering with the proper folding structure.

Keywords

References

  1. Alsolamy S, Arabi YM. 2015. Infection with Middle East respiratory syndrome coronavirus. Can. J. Respir. Ther. 51:102.
  2. Scobey T, Yount BL, Sims AC, Donaldson EF, Agnihothram SS, Menachery VD, et al. 2013. Reverse genetics with a fulllength infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. USA 110: 16157-16162. https://doi.org/10.1073/pnas.1311542110
  3. Wang C, Zheng X, Gai W, Zhao Y, Wang H, Wang H, et al. 2017. MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget 8: 12686-12694. https://doi.org/10.18632/oncotarget.8475
  4. Zhao G, He L, Sun S, Qiu H, Tai W, Chen J, et al. 2018. A novel nanobody targeting middle east respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV. J. Virol. 92.
  5. Lee K, Ko HL, Lee E-Y, Park H-J, Kim YS, Kim Y-S, et al. 2018. Development of a diagnostic system for detection of specific antibodies and antigens against Middle East respiratory syndrome coronavirus. Microbiol. Immunol. 62:574-584. https://doi.org/10.1111/1348-0421.12643
  6. Kim S, Kim S. 2018. Exploring the determinants of perceived risk of Middle East respiratory syndrome (MERS) in Korea. Int. J. Environ. Res. Public Health 15(6).
  7. Shubin Z, Li W, Poonia B, Ferrari G, LaBranche C, Montefiori D, et al. 2017. An HIV envelope gp120-Fc fusion protein elicits effector antibody responses in rhesus macaques. Clin. Vaccine Immunol. 24.
  8. Zhao B, Zhang X, Krummenacher C, Song S, Gao L, Zhang H, et al. 2018. Immunization with Fc-based recombinant epstein-barr virus gp350 elicits potent neutralizing humoral immune response in a BALB/c mice model. Front. Immunol. 9.
  9. Zhang Y, Zhou Z, Zhu SL, Zu X, Wang Z, Zhang LK, et al. 2019. A novel RSV F-Fc fusion protein vaccine reduces lung injury induced by respiratory syncytial virus infection. Antiviral Res. 165: 11-22. https://doi.org/10.1016/j.antiviral.2019.02.017
  10. Kuo TT, Aveson VG. 2011. Neonatal Fc receptor and IgGbased therapeutics. MAbs 3: 422-430. https://doi.org/10.4161/mabs.3.5.16983
  11. Zhao G, Du L, Ma C, Li Y, Li L, Poon VKM, et al. 2013. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol. J. 10.
  12. Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, et al. 2017. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. USA 114: E7348-E7357. https://doi.org/10.1073/pnas.1707304114
  13. Kebriaei A, Derakhshan M, Meshkat Z, Eidgahi MRA, Rezaee SA, Farsiani H, et al. 2016. Construction and immunogenicity of a new Fc-based subunit vaccine candidate against Mycobacterium tuberculosis. Mol. Biol. Rep. 43: 911-922. https://doi.org/10.1007/s11033-016-4024-9
  14. Jung SY, Kang KW, Lee EY, Seo DW, Kim HL, Kim H, et al. 2018. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine 36: 3468-3476. https://doi.org/10.1016/j.vaccine.2018.04.082
  15. Trivedi S, Miao C, Al-Abdallat MM, Haddadin A, Alqasrawi S, Iblan I, et al. 2018. Inclusion of MERS-spike protein ELISA in algorithm to determine serologic evidence of MERS-CoV infection. J. Med. Virol. 90: 367-371. https://doi.org/10.1002/jmv.24948

Cited by

  1. Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity vol.38, pp.18, 2019, https://doi.org/10.1016/j.vaccine.2020.02.089
  2. Functional Trimeric SARS-CoV-2 Envelope Protein Expressed in Stable CHO Cells vol.9, 2019, https://doi.org/10.3389/fbioe.2021.779359
  3. Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells vol.326, 2021, https://doi.org/10.1016/j.jbiotec.2020.12.005
  4. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants vol.12, pp.5, 2019, https://doi.org/10.1128/mbio.01813-21
  5. Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2 vol.6, pp.1, 2019, https://doi.org/10.1038/s41541-021-00303-w
  6. Enhancement of bioactivity, thermal stability and tumor retention by self-fused concatenation of green fluorescent protein vol.28, 2021, https://doi.org/10.1016/j.bbrep.2021.101112
  7. Development of a recombinant vaccine containing a spike S1-Fc fusion protein induced protection against MERS-CoV in human DPP4 knockin transgenic mice vol.299, 2022, https://doi.org/10.1016/j.jviromet.2021.114347